#### ![calendar-Icon](/themes/custom/cosmos/patterns/images/calendar-v2.svg)May 23, 2022 Driven by our passion for patients and grounded in our industry-leading pipeline of 45+ different compounds across 70+ development programs, Novartis is rapidly advancing novel cancer treatment approaches in areas of great medical need. var kPlayer = KalturaPlayer_55802022 || KalturaPlayer; var config = { targetId: "kaltura_player_6a9142f0dd833292866277", provider: { widgetId: "1_ntj4qwl7", partnerId: "2076321", uiConfId: "55802022" }, playback: { autoplay: false, autopause: false, muted: false, loop: false }, sources: { options: {}, startTime: 0 }, disableUserCache: "true", plugins: {}, sources: { options: {}, startTime: 0 }, ui: { showCCButton: false, settings: { showQualityMenu: true, showSpeedMenu: false }, components: { fullscreen: { disableDoubleClick: false } }, uiComponents: [ { presets: ['Playback', 'Live'], area: 'BottomBarRightControls', replaceComponent: 'Fullscreen', get: kPlayer.ui.components.Remove } ] } }; // Check and add plugins only if they exist if (kPlayer.plugins["download"]) { config.plugins.download = { disable: true }; } if (kPlayer.plugins["transcript"]) { config.plugins["playkit-js-transcript"] = { position: "right", // Default: bottom;('left', 'right', 'top', 'bottom') to enable transcript. expandMode: "over", // Default: alongside;('alongside', 'hidden', 'over') expandOnFirstPlay: false, showTime: true, downloadDisabled: false, printDisabled: false, disable: true }; } if (kPlayer.plugins["preventSeek"]) { config.plugins.preventSeek = { preventSeekForward: false, preventSeek: false }; } config.plugins.floating = { disable: true }; if (kPlayer.plugins["navigation"]) { config.plugins.navigation = { position: "right", expandMode: "over", expandOnFirstPlay: false, visible: false }; } if (kPlayer.plugins["hotspots"]) { config.plugins['playkit-js-hotspots'] = { disable: true }; } if (kPlayer.plugins["moderation"]) { config.plugins['playkit-js-moderation'] = { disable: true }; } if (kPlayer.plugins["info"]) { config.plugins['playkit-js-info'] = { disable: true }; } if (kPlayer.plugins["share"]) { config.plugins.share = { disable: true }; } config.ui.uiComponents = []; if (kPlayer.plugins["googleAnalytics"]) { config.plugins.googleTagManager = {}; config.plugins.googleTagManager.customEventsTracking = {}; config.plugins.googleTagManager.containerId = 'GTM-57RJQ5'; config.plugins.googleTagManager.customEventsTracking.custom = []; config.plugins.googleTagManager.customEventsTracking = { preset: { coreEvents: true, UIEvents: false, playlistEvents: false, castEvents: false } }; } // Ensure the global player registry array always exists, regardless of embed type. window.kalturaPlayerVideos = window.kalturaPlayerVideos || []; try { var thumbEmbedPromise = __thumbnailEmbed({config, mediaInfo: {entryId: "1_h881lx4d"}}); // __thumbnailEmbed() returns a Promise that resolves with the player instance // when the user clicks the thumbnail. Use .then() to capture the player directly. thumbEmbedPromise .then(function(player) { window.kalturaPlayerVideos.push(player); // Notify kaltura_datalayer.js that a new player is ready so it can // attach custom event listeners immediately, regardless of when // the user clicked the thumbnail relative to page load. document.dispatchEvent(new CustomEvent('kalturaPlayerReady', { detail: { player: player } })); }) .catch(function(error) { console.error(error); }); } catch (e) { console.error(e.message) } ## Every person’s cancer journey takes a different path One of the challenges of cancer is that there’s no single way to treat it, and sometimes no clear right way. ![3D illustration](/sites/novartis_com/files/styles/banner_image_1920/public/2022-05/novartis-oncology-congress-hub-banner.jpg?h=13bc9006&itok=DOM4LY08 "3D illustration") ## Join us at ASCO and EHA 2022 [Our virtual congress hub](https://www.hcp.novartis.com/virtual-congress/ "Our virtual congress hub") ### Our disease areas At Novartis, we push the limits of science to create technologies and platforms — from targeted and radioligand therapies, to cell and gene technologies, to immunotherapy — with potential to be new foundations for cancer care in areas with great unmet need. ![A doctor and a patient ](/sites/novartis_com/files/styles/crop_freeform/public/2022-05/breast-cancer-eha-asco.jpg.webp?itok=zm6C_qC6 "A doctor and a patient") **Breast cancer** Novartis is committed to driving measurable change with efforts to address disparities in breast cancer care. Our priority over the past 30 years and today is to deliver targeted therapies to potentially improve quality of life and extend lives for those diagnosed with breast cancer as we work toward a cure. ![Patient in his bed visited by his wife](/sites/novartis_com/files/styles/crop_freeform/public/2022-05/lung-cancer-eha-asco.jpg.webp?itok=xrgEPP5_ "Patient in his bed visited by his wife") **Lung cancer** Lung cancer is the number one cause of cancer-related deaths worldwide. With one of the most diverse drug development programs in the industry, our work in lung cancer is focused on making an impact for patients around the world. At Novartis, we are advancing the science to drive treatment for lung cancer. ![A doctor and a patient](/sites/novartis_com/files/styles/crop_freeform/public/2022-05/prostate-cancer-eha-asco.jpg.webp?itok=GuLD5aCl "A doctor and a patient") **Prostate cancer** We are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to explore the potential of our targeted radioligand therapy platform to address the unmet needs in prostate cancer. Our goal is to reduce the global disease burden, extend the lives of patients with prostate cancer, and elevate current standards of care. ![HCP and patient](/sites/novartis_com/files/styles/crop_freeform/public/2022-05/hematology-eha-asco.jpg.webp?itok=-Ul8jALS "HCP and patient") **Hematology** From targeted therapies, to precision cell and gene therapy, and immunotherapy – we have been pioneers in hematology, staying on the cutting edge in order to tackle blood cancers and serious blood disorders. Our research continues in new and different ways to harness the power of immunotherapy and potentially benefit a broader patient population than ever before. We are changing the hematological paradigm, transforming what it means to live with blood cancer or a serious blood disorder. ## Oncology and hematology stories [ ![Mother and her daughter](/sites/novartis_com/files/styles/cards_1_3/public/2022-05/mother-and-her-daughter.jpg.webp?itok=NSRQ0-z5 "Mother and her daughter") ### Addressing racial disparities in breast cancer screening Novartis today announced the launch of More Than Just Words, a multiyear commitment to promote health equity in breast cancer care. ](https://www.novartis.us/news/media-releases/novartis-commits-addressing-racial-disparities-breast-cancer-screening-treatment) [ ![Trees](/sites/novartis_com/files/styles/cards_1_3/public/2021-10/lung-cancer-hero.jpg.webp?itok=OA3Q-ayC "Trees") ### The search for new options for patients with lung cancer We’re working to bring the hope of advanced medicine to more patients. ](/stories/search-new-options-patients-lung-cancer) [ ![Scientist checking samples](/sites/novartis_com/files/styles/cards_1_3/public/2021-10/innovation-in-cml.jpg.webp?itok=zvogGmKr "Scientist checking samples") ### Two Decades of Pioneering Innovation in CML and Beyond With a breakthrough approval 20 years ago, Novartis opened the door to reimagine CML and other cancers. The pursuit of bold science didn’t stop there. ](/news/two-decades-pioneering-innovation-cml-and-beyond)